Particles that deliver vaccines directly to mucosal surfaces could defend against many infectious diseases.
Many viruses and bacteria infect humans through mucosal surfaces, such as those in the lungs, gastrointestinal tract and reproductive tract. To help fight these pathogens, scientists are working on vaccines that can establish a front line of defense at mucosal surfaces.
Vaccines can be delivered to the lungs via an aerosol spray, but the lungs often clear away the vaccine before it can provoke an immune response. To overcome that, MIT engineers have developed a new type of nanoparticle that protects the vaccine long enough to generate a strong immune response — not only in the lungs, but also in mucosal surfaces far from the vaccination site, such as the gastrointestinal and reproductive tracts.
Such vaccines could help protect against influenza and other respiratory viruses, or prevent sexually transmitted diseases such as HIV, herpes simplex virus and human papilloma virus, says Darrell Irvine, an MIT professor of materials science and engineering and biological engineering and the leader of the research team. He is also exploring use of the particles to deliver cancer vaccines.
“This is a good example of a project where the same technology can be applied in cancer and in infectious disease. It’s a platform technology to deliver a vaccine of interest,” says Irvine, who is a member of MIT’s Koch Institute for Integrative Cancer Research and the Ragon Institute of Massachusetts General Hospital, MIT and Harvard University.
Irvine and colleagues describe the nanoparticle vaccine in the Sept. 25 issue of Science Translational Medicine. Lead authors of the paper are recent PhD recipient Adrienne Li and former MIT postdoc James Moon.
Only a handful of mucosal vaccines have been approved for human use; the best-known example is the Sabin polio vaccine, which is given orally and absorbed in the digestive tract. There is also a flu vaccine delivered by nasal spray, and mucosal vaccines against cholera, rotavirus and typhoid fever.
To create better ways of delivering such vaccines, Irvine and his colleagues built upon a nanoparticle they developed two years ago. The protein fragments that make up the vaccine are encased in a sphere made of several layers of lipids that are chemically “stapled” to one another, making the particles more durable inside the body.
“It’s like going from a soap bubble to a rubber tire. You have something that’s chemically much more resistant to disassembly,” Irvine says.
This allows the particles to resist disintegration once they reach the lungs. With this sturdier packaging, the protein vaccine remains in the lungs long enough for immune cells lining the surface of the lungs to grab them and deliver them to T cells. Activating T cells is a critical step for the immune system to form a memory of the vaccine particles so it will be primed to respond again during an infection.
Stopping the spread of infection
In studies of mice, the researchers found that HIV or cancer antigens encapsulated in nanoparticles were taken up by immune cells much more successfully than vaccine delivered to the lungs or under the skin without being trapped in nanoparticles.
HIV does not infect mice, so to test the immune response generated by the vaccines, the researchers infected the mice with a version of the vaccinia virus that was engineered to produce the HIV protein delivered by the vaccine.
Mice vaccinated with nanoparticles were able to quickly contain the virus and prevent it from escaping the lungs. Vaccinia virus usually spreads to the ovaries soon after infection, but the researchers found that the vaccinia virus in the ovaries of mice vaccinated with nanoparticles was undetectable, while substantial viral concentrations were found in mice that received other forms of the vaccine.
Mice that received the nanoparticle vaccine lost a small amount of weight after infection but then fully recovered, whereas the viral challenge was 100 percent lethal to mice who received the non-nanoparticle vaccine.
“Giving the vaccine at the mucosal surface in the nanocapsule form allowed us to completely block that systemic infection,” Irvine says.
The Latest on: Nanoparticle vaccine
- Influenza Vaccine Market 2019: Propelling Growth | Increasing Product Approvalon June 19, 2019 at 7:24 am
Moreover, in 2017, FluGen, Inc., received US$ 14.4 million by Department of Defense for evaluating Universal Flu Vaccine, RedeeFlu, of Mismatched Strains. In Sep 2017, Novavax initiating phase1/2 ... […]
- Personalized nanovaccines are safe, well tolerated, and have an effect in melanomaon June 13, 2019 at 12:38 am
Nevertheless, there is an unmet need for powerful, yet safe vaccines. Nanoparticles, in particular porous silicon nanoparticles, present ideal characteristics to formulate nanovaccines, as a result of ... […]
- Frederick research centers look to advance technology through partnershipson June 12, 2019 at 6:43 pm
A vaccine for HIV. Nanoparticles. A topical ointment for sickle cell disease. Those are just three examples of technologies discussed at a showcase held by the Frederick National Laboratory for Cancer ... […]
- Gold Nanoparticles Market: Worldwide Growth, Trends, and Forecasts 2019-2024 - ResearchAndMarkets.comon June 12, 2019 at 10:47 am
Gold nanoparticles are used to deliver multiple drugs molecules, vaccines, recombinant proteins, or nucleotides into their targets, and can also control the volume of drug released via biological ... […]
- Novavax CFO John Trizzino to Discuss Future of Influenza Vaccines on Industry Panel at 2019 BIO International Conventionon June 11, 2019 at 11:30 am
Its two priority programs are ResVax™, its RSV vaccine for infants via maternal immunization, and NanoFlu™, its quadrivalent influenza nanoparticle vaccine. Novavax’ proprietary recombinant ... […]
- Novavax, Inc.: Novavax CFO John Trizzino to Discuss Future of Influenza Vaccines on Industry Panel at 2019 BIO International Conventionon June 4, 2019 at 3:17 pm
Its two priority programs are ResVax, its RSV vaccine for infants via maternal immunization, and NanoFlu, its quadrivalent influenza nanoparticle vaccine. Novavax' proprietary recombinant technology ... […]
- New Finding Advances the Search for a Universal Flu Vaccineon June 3, 2019 at 11:52 am
trial of a vaccine that aims to induce hemagglutinin stem antibodies. “His approach is to take the stem part of the hemagglutinin and put it onto a nanoparticle that induces a very good immune ... […]
- Technologies Enabling Next Generation Vaccine Development, 2019 Research Reporton May 31, 2019 at 1:56 am
Vaccine Delivery platforms: This section covers various nanoparticle-based vaccine delivery platforms such as nanoparticles of biological (self-assembling proteins) and non-biological origin ... […]
- Technologies Enabling Next Generation Vaccine Developmenton May 27, 2019 at 12:50 pm
Vaccine Delivery platforms: This section covers various nanoparticle-based vaccine delivery platforms such as nanoparticles of biological (self-assembling proteins) and non-biological origin ( ... […]
- Novavax Scientific Leadership to Present RSV Maternal Immunization Program Phase 3 Data and Participate in Panel on COPD at World Vaccine Congresson April 9, 2019 at 4:27 pm
Glenn, M.D., President of Research and Development, will share data from its global Phase 3 clinical trial of ResVax™, the respiratory syncytial virus (RSV) fusion (F) protein recombinant nanoparticle ... […]
via Google News and Bing News